The startup has raised a pre-seed round from Techstars Boston and Blackbird Venture’s pre-seed program and has started pilot programs and clinical studies with eight institutions. BioticsAI's primary focus is on second trimester anomaly screenings, where 90% of potential fetal abnormalities are screened for. However, if successful, the company plans to expand its AI diagnostics platform to other fields such as gynecology, urology, and neonatology.
Key takeaways:
- BioticsAI is a startup that has developed an AI-based platform that integrates with ultrasound machines to prevent misdiagnosis of fetal malformations.
- The platform processes images and videos from screenings to identify malformations, validate the quality of the screening, and automatically generate reports, aiming to mitigate the shortage of obstetrics professionals in many regions.
- BioticsAI's platform can identify incomplete screenings, analyze images for proper capture according to international standards, and use AI to help doctors identify fetal malformations with a claimed accuracy of 96%.
- The startup has raised a pre-seed round from Techstars Boston and Blackbird Venture’s pre-seed program, and has started pilot programs and clinical studies with eight institutions.